Literature DB >> 3876202

Vertigo. Current concepts in management.

W J Oosterveld.   

Abstract

Vertigo is not a disease, but a symptom. The management of vertigo requires more than the treatment of the symptom alone, as it concerns the whole physical and psychological condition of the patient. In addition to causal treatment, symptomatic treatment is needed in many cases. This specific treatment consists of vestibular exercises and drug therapy. The efficacy and use of the different drugs available are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876202     DOI: 10.2165/00003495-198530030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  Rehabilitation in Vestibular Injuries.

Authors:  F S Cooksey
Journal:  Proc R Soc Med       Date:  1946-03

2.  Vestibular Injuries.

Authors:  T Cawthorne
Journal:  Proc R Soc Med       Date:  1946-03

3.  Pharmacologic properties of anti-vertiginous drugs.

Authors:  J R Leonard; R A Lawrence
Journal:  Eye Ear Nose Throat Mon       Date:  1971-10

4.  The vertiginous syndrome.

Authors:  W J Oosterveld
Journal:  Adv Otorhinolaryngol       Date:  1983

Review 5.  Treatment of vertigo based on habituation. 1. Physio-pathological basis.

Authors:  M E Norré; W De Weerdt
Journal:  J Laryngol Otol       Date:  1980-07       Impact factor: 1.469

6.  Singular neurectomy update.

Authors:  R R Gacek
Journal:  Ann Otol Rhinol Laryngol       Date:  1982 Sep-Oct       Impact factor: 1.547

Review 7.  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

8.  Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study.

Authors:  W J Oosterveld
Journal:  J Laryngol Otol       Date:  1984-01       Impact factor: 1.469

9.  The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.

Authors:  W J Oosterveld
Journal:  Arzneimittelforschung       Date:  1980

10.  Astemizole: its use in patients with chronic vertigo and eng signs--a pilot study of a new drug.

Authors:  J S Turner; R T Jackson
Journal:  Laryngoscope       Date:  1983-07       Impact factor: 3.325

View more
  7 in total

1.  Chronic hemidystonia following acute dystonic reaction to thiethylperazine.

Authors:  F J Jiménez-Jiménez; A Vazquez; P Garcia-Ruiz; D Garcia-Urra; E V De Seijas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-06       Impact factor: 10.154

2.  Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study.

Authors:  Ales Hahn; Miroslav Novotný; Penko M Shotekov; Zdenek Cirek; Irene Bognar-Steinberg; Wolfgang Baumann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 3.  Antivertigo medications and drug-induced vertigo. A pharmacological review.

Authors:  O Rascol; T C Hain; C Brefel; M Benazet; M Clanet; J L Montastruc
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

4.  Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo : A Double-Blind, Randomised Clinical Study.

Authors:  Zdenek Cirek; Mario Schwarz; Wolfgang Baumann; Miroslav Novotny
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

5.  Management of acute vertigo with betahistine.

Authors:  R A Bradoo; N K Nerurkar; J B Mhapankar; S F Patil; D G Kute
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2000-04

6.  Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.

Authors:  Fulvio Plescia; Pietro Salvago; Francesco Dispenza; Giuseppe Messina; Emanuele Cannizzaro; Francesco Martines
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

7.  Studies on the Preparation, Characterization, and Solubility of 2-HP-β-Cyclodextrin-Meclizine HCl Inclusion Complexes.

Authors:  Sj George; Dt Vasudevan
Journal:  J Young Pharm       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.